Vivos Therapeutics

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Highlands Ranch, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q3 2022

Earnings data Q2 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vivos Therapeutics reports revenue decline but eyes growth through FDA clearances

Vivos Therapeutics reported a decline in revenue for Q1 2024 but showcased improved operating performance and cash flow management. The company is focused on revenue growth initiatives, strategic collaborations, and expanding product access to achieve cash flow positivity by late 2024 or early 2025. Challenges include revenue decline and the need to reduce dependency on dentistry channel.

Vivos Therapeutics reports robust Q2 earnings, eyes market expansion

Vivos Therapeutics delivered a strong Q2 2024 performance with revenue growth, improved margins, and cost management driving financial stability and operational efficiency.
The company's strategic initiatives, including the alliance with a sleep clinic and FDA clearances, position it well for market expansion and revenue enhancement.
While challenges in maintaining growth and managing costs persist, Vivos has opportunities to leverage its strengths in customer loyalty, financial stability, and market reach for sustainable growth.
By focusing on revenue optimization, cost control, and strategic partnerships, Vivos aims to enhance profitability, drive innovation, and capture new market opportunities.

Vivos Therapeutics reports revenue growth and strategic expansion plans

Vivos Therapeutics showed revenue growth and improved gross profit margins in Q3 2024. Despite challenges in net loss and cash burn, the company is optimistic about achieving positive cash flow and expanding its market presence through strategic alliances.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Littleton, CO.

Vinco Ventures

Citius Pharmaceuticals

Diffusion Pharmaceuticals

Powerbridge Technologies Co Ltd

Seanergy Maritime Hlds

Weidai Ltd - ADR

Does your list of penny stocks to watch include these 7 hot small-caps? The post Making a List of Penny Stocks to Buy?

Making a List of Penny Stocks to Buy? Here's 7 to Watch in Summer 2021

Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q1 2021 Results - Earnings Call Transcript

Management to Host Conference Call Today at 5:00 pm ET Management to Host Conference Call Today at 5:00 pm ET

Vivos Therapeutics Reports First Quarter 2021 Financial Results and Operational Update

HIGHLANDS RANCH, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos”), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the closing of its underwritten follow-on public offering of 4,600,000 shares of its common stock. The offering consisted of 4,000,000 shares of its common stock, as well as an additional 600,000 shares pursuant to the exercise in full of the underwriters' option to purchase additional shares of common stock, at a public offering price of $6.00 per share.

Vivos Therapeutics Announces Closing of Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

HIGHLANDS RANCH, Colo., May 06, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos”), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the pricing of its underwritten follow-on public offering of 4,000,000 shares of its common stock at a public offering price of $6.00 per share.

Vivos Therapeutics Announces Pricing of $24 Million Follow-On Offering

Sleeping well plays an essential role in physical health. In fact, it is part of the recovery, healing and repair process of many body functions.

Vivos Therapeutics Leads the Battle Against Obstructive Sleep Apnea (OSA)

HIGHLANDS RANCH, Colo., April 14, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the appointment of Mimi Guarneri, MD, FACC as an independent consultant serving in the role of Medical Director of Clinical Education, effective April 1, 2021.

Vivos Therapeutics Announces Integrative Cardiologist Dr. Mimi Guarneri as New Medical Director of Clinical Education

Vivos management to present at 9:00 am EDT on April 14, 2021 Vivos management to present at 9:00 am EDT on April 14, 2021

Vivos Therapeutics to Participate at the Emerging Growth Conference

Inspire Medical Systems Inc

ResMed

Three stocks to have on your radar in the healthcare space.

Investing in Sleep Apnea Companies

Vivos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update

Vivos management to present at 1:30 pm Eastern Time on March 23, 2021

Vivos Therapeutics to Participate at the Q1 Virtual Investor Summit

Physicians and Dentists Collaborate to Offer Vivos System Treatment to Patients Suffering from Sleep Apnea Physicians and Dentists Collaborate to Offer Vivos System Treatment to Patients Suffering from Sleep Apnea

Vivos Therapeutics Announces the Opening of the First Pneusomnia Integrated Medical-Dental Sleep Center

If Approved for Clearance, Vivos' Updated Device Will Treat Mild to Moderate Sleep Apnea and Expand Insurance Reimbursement to include Medicare Coverage If Approved for Clearance, Vivos' Updated Device Will Treat Mild to Moderate Sleep Apnea and Expand Insurance Reimbursement to include Medicare Coverage

Vivos Therapeutics Submits FDA 510(k) Application for the Vivos mmRNA Oral Appliance

Internationally Recognized Medical and Dental Industry Veterans Will Work Closely with Vivos Management to Drive Further Commercial Success Internationally Recognized Medical and Dental Industry Veterans Will Work Closely with Vivos Management to Drive Further Commercial Success

Vivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts

Marker Therapeutics Inc

Tenet Healthcare

Cyclo Therapeutics, Inc.

Cyclo Therapeutics (NASDAQ: CYTH) shares are trading higher Tuesday after the company announced "positive" efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann-Pick Disease Type C. Cyclo Therapeutics is a U.S.-based biotechnology firm engaged in the marketing and sales of cyclodextrins (CD) and related products for food, pharmaceutical, and other industries to be used in diagnostics and specialty drugs with continuing growth in research and new product development.

Why Cyclo, Vivos Therapeutics And More Are Moving Today

HIGHLANDS RANCH, Colo., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos”) today announced the closing of its initial public offering of 4,025,000 shares of its common stock. The offering consisted of 3,500,000 shares of its common stock, as well as an additional 525,000 shares pursuant to the exercise in full of the underwriters' option to purchase additional shares of common stock, at a public offering price of $6.00 per share. Vivos' common stock is listed on the Nasdaq Capital Market under the ticker symbol “VVOS.”

Vivos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

HIGHLANDS RANCH, Colo., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“ Vivos ”), a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, today announced the pricing of its initial public offering of 3,500,000 shares of its common stock at a public offering price of $6.00 per share. The shares of common stock are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “VVOS” on Friday, December 11, 2020.

Vivos Therapeutics Announces Pricing of $21M Initial Public Offering

News for Vivos Therapeutics Stock (VVOS)